Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $167.3 million versus the consensus estimate of $165.04 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.